This week, we round out our discussion on the early stage breast cancer, turning our attention to the triple negative subtype. Once again, there are a lot of trials and data, but be sure to check out the show notes for the highlights!
Content:
- What is TNBC?
-What is the data to support the use of neoadjuvant therapy in this disease?
- What is "pathologic CR" and how is different than "residual cancer burden"?
- Can we ever omit neoadjuvant therapy?
- What are our options for chemotherapy regimens in neoadjuvant and adjuvant setting?
** This episode has been sponsored by HemOnc.org
** Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodes
Love what you hear? Tell a friend and leave a review on our podcast streaming platforms!
Twitter: @TheFellowOnCall
Instagram: @TheFellowOnCall
Listen in on: Apple Podcast, Spotify, and Google Podcast
The Fellow on Call: The Heme/Onc Podcast